Libtayo has been approved for adults when curative surgery or radiation is not appropriate Libtayo has been approved for adults when curative surgery or radiation is not appropriate The Nationail ...

Regeneron has fleshed out additional positive data for blockbuster immunotherapy Libtayo (cemiplimab) as an adjuvant therapy in high-risk cutaneous squamous cell carcinoma (CSCC), as rival PD-1 ...

New authorisation marks major milestone in earlier treatment of skin cancer The European Commission has approved Libtayo (cemiplimab) as the first and only immunotherapy for adult patients with ...

NEW YORK (CBSNewYork)-- It's the second-most common cancer in the U.S., yet you've probably never heard of it. It's a kind of skin cancer called squamous cell and there are a million cases of it every ...

Regeneron's PD-1 inhibitor Libtayo could find wider use for a form of skin cancer known as cutaneous squamous cell carcinoma after showing efficacy in a pivotal trial as adjuvant therapy for patients ...

TARRYTOWN, N.Y. - The U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals’ (NASDAQ:REGN) Libtayo (cemiplimab-rwlc) as an adjuvant treatment for adult patients with cutaneous ...

Final thoughts on unmet needs in the management of BCC and CSCC and how to approach future treatment of these diseases. Transcript Omid Hamid, MD: While we have made huge inroads into the therapy for ...

Increased odds of positive margins were associated with tumors from the head and neck (OR 2.78), excision in a primary care facility (OR 2.20), and increased tumor thickness (OR 1.56). Increased odds ...